[go: up one dir, main page]

AR062856A1 - Compuestos derivados de aziridina utilizados en marcacion radioactiva por fluoracion del compuesto - Google Patents

Compuestos derivados de aziridina utilizados en marcacion radioactiva por fluoracion del compuesto

Info

Publication number
AR062856A1
AR062856A1 ARP070104087A ARP070104087A AR062856A1 AR 062856 A1 AR062856 A1 AR 062856A1 AR P070104087 A ARP070104087 A AR P070104087A AR P070104087 A ARP070104087 A AR P070104087A AR 062856 A1 AR062856 A1 AR 062856A1
Authority
AR
Argentina
Prior art keywords
fluoration
composite
compounds derived
aziridine
radioactive marking
Prior art date
Application number
ARP070104087A
Other languages
English (en)
Inventor
Keith Graham
Ananth Srinivasan
Timo Stellfeld
Thomas Brumby
Linjing Mu
Jessica Becaud
Ulrike Volgtmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07090001A external-priority patent/EP1944288A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR062856A1 publication Critical patent/AR062856A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/22—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C07D203/24—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos adecuados para ser marcados o ya marcados radioactivamente con 18F, métodos para preparar tales compuestos y uso de los mismos para diagnostico para imágenes. Un compuesto caracterizado porque comprende un anillo de aziridina apropiadamente activado con fines de marcacion, en el cual un radical agente de direccionamiento, está unido, ya sea directamente o a través de un conector apropiado, al anillo de aziridina o a un anillo carbocíclico o heterocíclico de cinco miembros que está fusionado al anillo de aziridina.
ARP070104087A 2007-01-09 2007-09-14 Compuestos derivados de aziridina utilizados en marcacion radioactiva por fluoracion del compuesto AR062856A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07090001A EP1944288A1 (en) 2007-01-09 2007-01-09 Radiolabelling via fluorination of aziridines
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
AR062856A1 true AR062856A1 (es) 2008-12-10

Family

ID=38941926

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104087A AR062856A1 (es) 2007-01-09 2007-09-14 Compuestos derivados de aziridina utilizados en marcacion radioactiva por fluoracion del compuesto

Country Status (24)

Country Link
US (1) US20090022664A1 (es)
EP (1) EP2099747A1 (es)
JP (1) JP2010522140A (es)
KR (1) KR20090096716A (es)
AR (1) AR062856A1 (es)
AU (1) AU2007343454A1 (es)
BR (1) BRPI0720884A2 (es)
CA (1) CA2674408A1 (es)
CL (1) CL2007002673A1 (es)
CO (1) CO6220852A2 (es)
CR (1) CR10917A (es)
DO (1) DOP2009000173A (es)
EC (1) ECSP099505A (es)
MA (1) MA31175B1 (es)
MX (1) MX2009007395A (es)
NO (1) NO20092813L (es)
PA (1) PA8747801A1 (es)
PE (1) PE20081661A1 (es)
RU (1) RU2009130455A (es)
SV (1) SV2009003328A (es)
TN (1) TN2009000233A1 (es)
TW (1) TW200829275A (es)
UY (1) UY30594A1 (es)
WO (1) WO2008083729A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784774B2 (en) 2011-09-16 2014-07-22 General Electric Company Labeled molecular imaging agents and methods of use
US9468692B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
US9468693B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
NL2014828B1 (en) * 2015-05-20 2017-01-31 Out And Out Chemistry S P R L Method of performing a plurality of synthesis processes of preparing a radiopharmaceutical in series, a device and cassette for performing this method.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954994A (en) * 1968-10-03 1976-05-04 Pfizer Inc. Intermediates for preparing hipolipemic agents and method of lowering the blood lipid level in mammals with said agents
JPS5810380B2 (ja) * 1975-01-31 1983-02-25 三共株式会社 ペプチドノ セイホウ
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP2098514A1 (en) * 1999-07-21 2009-09-09 The Trustees Of The University Of Pennsylvania Preparation of compounds useful for the detection of hypoxia
SE9903998D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2004014377A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
GB0222909D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
US6875784B2 (en) * 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
CN1212307C (zh) * 2003-07-23 2005-07-27 中国科学院上海有机化学研究所 一种合成β－氟胺化合物的方法
EP1799637A1 (en) * 2004-09-23 2007-06-27 Amgen, Inc Substituted sulfonamidopropionamides and methods of use
CA2602146A1 (en) * 2005-04-07 2006-10-19 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
MA31175B1 (fr) 2010-02-01
NO20092813L (no) 2009-09-22
CR10917A (es) 2009-08-27
PA8747801A1 (es) 2009-08-26
RU2009130455A (ru) 2011-02-20
BRPI0720884A2 (pt) 2014-03-25
KR20090096716A (ko) 2009-09-14
CA2674408A1 (en) 2008-07-17
CO6220852A2 (es) 2010-11-19
JP2010522140A (ja) 2010-07-01
UY30594A1 (es) 2008-09-02
SV2009003328A (es) 2009-12-14
WO2008083729A1 (en) 2008-07-17
MX2009007395A (es) 2009-07-17
CL2007002673A1 (es) 2008-07-18
TN2009000233A1 (en) 2010-10-18
PE20081661A1 (es) 2009-01-18
EP2099747A1 (en) 2009-09-16
DOP2009000173A (es) 2010-10-31
AU2007343454A1 (en) 2008-07-17
ECSP099505A (es) 2009-08-28
US20090022664A1 (en) 2009-01-22
TW200829275A (en) 2008-07-16

Similar Documents

Publication Publication Date Title
ECSP11010808A (es) Daa-piridina como ligando del receptor periférico de benzodiazepina para el diagnóstico por imágenes y para el tratamiento farmacéutico
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
AR102105A1 (es) Conjugado radiofarmacéutico
UY30595A1 (es) Métodos de marcacion con fluor radioactivo
MY188934A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
DOP2016000163A (es) 5-flúor-4-imino-3-(alquil/alquilo sustituido)-1-(arilsulfonil)-3,4-dihidropirimidin-2(1h)-ona y los procesos para su preparación
CR20110670A (es) Nuevos conjugados, su preparación y su aplicación terapéutica
AR080301A1 (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
MX391369B (es) Productos radiofarmaceuticos, agentes de radioimagenologia, y uso de los mismos.
WO2010014933A3 (en) Psma-binding agents and uses thereof
BRPI0719141A2 (pt) Sistema e método para gerar imagem de câncer de próstata, meio legível por computador, e, usos do sistema e de tomografia óptica difusa
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CO6541613A2 (es) Combinaciones de un antagonista de los receptores muscarínicos y un agonista del adreno-receptor beta 2
MX348733B (es) Composiciones de radiorastreador de peptido.
CL2016002469A1 (es) Sulfamidasa modificada y su producción
AR062856A1 (es) Compuestos derivados de aziridina utilizados en marcacion radioactiva por fluoracion del compuesto
MX2011010295A (es) Reactivos de radiomarcado y metodos.
BR112012021579A2 (pt) traçador de tomografia por emissão de pósitron, composto precursor, método para preparar o composto precursor, cassete, composição radiofarmacêutica, método de formação de imagem por tomografia por emissão de pósitron, e, método para diagnose de uma condição.
UY30596A1 (es) Marcacion con fluor radioactivo
AU2010332841A8 (en) Prostate specific membrane antigen inhibitors
CR20150642A (es) Preparado farmaceutico
CY1116283T1 (el) Δοσολογια μοναδας apadenoson
WO2008151003A3 (en) Novel fluorine-18 labeled rhodamine derivatives for myocardial perfusion imaging with positron emission tomography
DOP2009000060A (es) Derivados de silicio para obtencion de imágenes por tomografia de emision de positrones (pet)
PH12019502665A1 (en) 18f-labelled compound for prostate cancer diagnosis, and use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure